Washington Vertex Pharmaceuticals

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

FDA approves new painkiller designed to avoid opioid addiction risk

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to treating pain in more than 20 years,

CNBC on MSN · 14h

FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

Tribune-Star · 14h

FDA approves painkiller designed to eliminate the risks of addiction associated with opioids

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids. The Food and Drug Administration approved the pill

17hon MSN

Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

36m

Vertex Pharmaceuticals price target raised to $550 from $535 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

Black boxes found from crashed jet and FDA approves a new nonopioid painkiller: Morning Rundown

Plus, NBC News spoke to trans service members about their thoughts on President Trump's executive order banning trans people from enlisting and serving in the military.

Vertex Pharmaceuticals’ JOURNA VX: Navigating Market Challenges Despite Promising Financial Outlook

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results